Suven Life Sciences Ltd announced additional disclosure regarding an Extra-Ordinary General Meeting on June 5, 2025, including details on a proposed preferential issue of warrants for ABAKKUS DIVERSIFIED ALPHA FUND, which will issue 29,85,000 warrants, representing 1.06% post-issue shareholding assuming full conversion.